PROCEPT BioRobotics (PRCT) News Today

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is facing continued investor attention after several law firms announced or promoted securities-fraud class actions. The litigation headlines are likely weighing on the stock, which has recently traded near its 52-week low and below its 200-day moving average.

• Negative Sentiment: Multiple firms, including Kaplan Fox, Hagens Berman and others, say a securities class action has been filed on behalf of investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The lead-plaintiff deadline is September 22, 2026. Kaplan Fox class action announcement
• Negative Sentiment: The allegations center on purportedly undisclosed inventory problems, weaker-than-expected handpiece sales and repeated late-quarter bulk discounts that allegedly left customers with excess inventory. Hagens Berman said the disclosures contributed to an approximately 18% stock decline; the claims have not been proven in court. Hagens Berman securities-fraud lawsuit announcement
• Neutral Sentiment: Three executive vice presidents reported small stock sales totaling $21,851. The transactions represented less than 0.4% of each executive’s holdings and were made to cover tax withholding on vested equity awards, limiting their significance as a signal of management’s outlook. SEC insider transaction filing
• Neutral Sentiment: A report showing zero short interest and a zero-day days-to-cover ratio appears inconsistent with the surrounding data and is unlikely to provide a meaningful trading signal.

For investors, the immediate risk is reputational and legal uncertainty, while the underlying business concern is whether inventory levels, discounting and handpiece demand could pressure future revenue, margins and cash flow. PROCEPT’s latest reported quarter showed revenue growth but a net loss, leaving the litigation allegations as an additional overhang.